Malignant pleural effusion is a common complication which occurs in approximately 15% of lung cancer patients and is a significant problem detrimental to a patient‘s quality of life.6 Intrapleural therapy by insertion of a catheter intercostally, and infusion of chemotherapeutic agents have been widely used for the treatment of symptomatic MPE.13 VEGF is a potent growth factor for endothelial cells and prompts the formation of new blood vessels. This evidence concerns the gene VEGFA and lung cancer.